Mitchell C Benson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9105041/publications.pdf

Version: 2024-02-01

21 papers 1,530 citations

1039406 9 h-index 19 g-index

22 all docs $\begin{array}{c} 22 \\ \text{docs citations} \end{array}$

times ranked

22

2074 citing authors

#	Article	IF	CITATIONS
1	Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. Journal of Urology, 1992, 147, 815-816.	0.2	669
2	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 2018, 173, 515-528.e17.	13.5	540
3	Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment Failure. Journal of Urology, 2014, 192, 1633-1638.	0.2	74
4	Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer. PLoS ONE, 2016, 11, e0154507.	1.1	48
5	Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. , 1999, 84, 360-364.		46
6	Who Really Benefits From Nephron-sparing Surgery?. Urology, 2014, 84, 860-868.	0.5	35
7	Flow cytometric analysis of localized adenocarcinoma of the prostate: The use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy. Prostate, 1990, 17, 155-164.	1.2	27
8	Predicting Renal Parenchymal Loss after Nephron Sparing Surgery. Journal of Urology, 2015, 194, 658-663.	0.2	23
9	Percutaneous Approach to Treatment of Indiana Pouch Stones. Journal of Urology, 1994, 151, 690-692.	0.2	16
10	Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy. Prostate, 2016, 76, 226-234.	1.2	12
11	The Flow Cytometric Analysis of Undescended Testes in Children. Journal of Urology, 1990, 144, 494-498.	0.2	9
12	Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 787.e9-787.e15.	0.8	9
13	Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance. Clinical Genitourinary Cancer, 2018, 16, e425-e435.	0.9	8
14	BILATERAL INTRARENAL ADRENAL GLANDS IN CADAVERIC DONOR KIDNEYS RESEMBLING RENAL CELL CARCINOMA ON INTRAOPERATIVE FROZEN SECTION. Journal of Urology, 2001, 166, 1820-1821.	0.2	4
15	Bladder Preservation for Patients With Bladder Paragangliomas: Case Series and Review of the Literature. Urology, 2020, 143, 194-205.	0.5	4
16	Reply to Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate, 1998, 37, 138-139.	1.2	2
17	Reducing unnecessary biopsies while detecting significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 348.	0.8	1
18	The impact of clinically significant discrepancies from primary pathological review of transurethral bladder resection specimens upon repeat review at a tertiary care center Journal of Clinical Oncology, 2013, 31, 4552-4552.	0.8	1

#	Article	IF	CITATIONS
19	Natural history of clinical complete response to neoadjuvant chemotherapy for urothelial carcinoma of the bladder: Updated single-institution experience Journal of Clinical Oncology, 2016, 34, 4537-4537.	0.8	1
20	Oncologic outcomes of complete transurethral resection prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer Journal of Clinical Oncology, 2020, 38, e17029-e17029.	0.8	1
21	Predictors of treatment outcomes following salvage intravesical chemotherapy in patients with prior BCG treatment Journal of Clinical Oncology, 2016, 34, e16015-e16015.	0.8	O